This episode explores the pivotal shift from traditional clinical trial data to the increasing demand for continuous Real-World Evidence (RWE) for medical devices. We delve into why global regulators and payers now require robust post-market data to prove a device's long-term safety, effectiveness, and value. We also unpack the significant infrastructure and analytical challenges that MedTech companies face in building a compliant and effective RWE program.

Key Questions:

- What is the difference between Real-World Data (RWD) and Real-World Evidence (RWE)?

- Why are traditional clinical trials no longer sufficient for market approval and reimbursement?

- How do new regulations like the EU MDR impact post-market data collection requirements?

- What specific evidence are payers looking for to determine a device's cost-effectiveness?

- What are the main challenges companies face when building an RWE generation system?

- How can a strong RWE strategy provide a competitive advantage?

As regulatory demands for Real-World Evidence intensify, having a proactive strategy is essential. Pure Global helps MedTech and IVD companies design and implement robust post-market surveillance and data analysis programs. Our blend of local regulatory expertise and advanced AI tools simplifies the process of gathering, analyzing, and submitting the evidence needed to maintain and expand global market access. We turn your post-market obligations into a strategic advantage. To learn more about our services, visit us at https://pureglobal.com/, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.